Bal pharma extends its foothold in the pharma market

Bal Pharma extends its foothold in the pharma market
Bal pharma aim expansion plans in Andhrapradesh
Bangalore, Karnataka, July 29, 2008 / -- BAL PHARMA LIMITED, (BSE, NSE: BAL PHARMA) one ofIndia’s leading Pharma companies, has announced their expansion plans in the Andhra Pradesh market with aview to garner control over a market in which they already have a substantial presence and market share. BalPharma, operates in domestic market through its four divisions viz MSD (Multi Specialty Division), Glyduz(Diabetes –Specialty), Servetus (Cardiology-specialty) & Bal Vedics (Ayurvedic Division) with a strong and dynamicfield force of 600 Marketing executives and managers. With the Current year Man power expansion to 50 marketingexecutives, the sales in A.P is expected to increase three folds in this financial year.
Speaking on the refurbishing of its marketing and distribution force, Mr. Deepak Sarda, Vice President, Marketing,Bal Pharma limited said “We have taken this strategic step to market aggressively in South India with a primefocus in Andhra Pradesh; one of India’s largest pharma market. The company has a strong establishment in otherthree states of South and feels this is a right time to look towards largest South market, especially when thecompany has won acknowledgement at the international level too. We are looking at an exponential growth takingthe present AP market to 20 crores in the next 4 years. This step will also support our vision to be a 1000 crorecompany in the near future.” Bal Pharma Limited has embarked on a greater expansion keeping in view of the ambitious vision plan of 1000 Crby 2012.The total Indian Pharma market is estimated to be around 32409 Crores growing at the rate of 15 %.
Andhra Pradesh contributes 9.5 % to total Indian Pharmaceutical Market. The pharmaceutical market in AndhraPradesh is estimated to be 2900 Crores growing at the rate of 14 %. In A.P, the total market size of the therapeuticsegments like Anti-Diabetes (OHA’s) is 130 Cr, Cardiology: 331 Cr, PPI: 130 Cr, Antihistamines: 51 Cr,Gynecology (Nutraceuticals like Calcium & Iron Preparations): 94 Cr, & Antibiotics groups like Macrolide 44 Cr,.
Currently, Bal Pharma represents in these therapeutic segments of A.P market with its well established brands likeAziwin ,Diabend-M, Lipofix and new introductions, added Mr. Sarda.
Recently, Bal Pharma has already introduced few promising molecules like TELONG (Telmisartan 20, 40 &Telmisartan-H) for Hypertension, RABIFIX (Rabeprazole 20 mg & Rabeprazole 20 mg with Domperidone 30 mg) PPI, GLYVOG (Voglibose 0.2 & 0.3 mg) for Diabetes & AZIWIN-AX(Azithromycin with Ambroxol) for Respiratory infections. Bal Pharma plans to launch many molecules in various therapeutic segments like Cephalosporin’s, Anti-Arthritis,Nutraceuticals, Anti Hypertensives, Anti-Diabetes (OHA’s), Anti-Allergics & New Lipid lowering Agents, on all Indiabasis which will boost up the net sales of Bal Pharma in the months to come.
Going ahead, the company is planning to file more DMFs in next few months, and this would comprise of a basketof products being required by the market as the country has an advanced healthcare system and demand for alltypes of pharmaceuticals is high. The company would be entering 15 new countries within the next financial year.
With manpower of more than 1000 in the company, the company is committed to develop, manufacture and marketinnovative Pharma products. The company with its international quality systems, excellent infrastructure andoutstanding manpower skills is working aggressively to become a reckoning name in the Indian & GlobalPharmaceutical industry.
Notes to Editor
Bal Pharma Ltd, a pharmaceutical company listed at Bombay Stock Exchange & National Stock Exchange is aleading manufacturer, marketer and exporter of pharmaceutical products in India and abroad. Established in 1993,the company has an envious track record of providing its immaculate services in the health care market. Thecompany’s strength spans a range of Branded formulations, APIs, Generics including Parentereals, andIntermediates, to Herbals. Bal Pharma has three manufacturing units, one for APIs coupled with R & D, the second for formulations both located at Bangalore and a third unit for Parentereals at Pune; all equipped with ultramodernstate-of-the-art technology. All units conform to the GMP standards as laid down by WHO. Bal Pharma is also oneof the top companies in the country having the latest Form Fill and Seal (FFS) technology. For more information, please contact:
Veena Dsouza
Account Manager
(L) 23337344
copyright 2014 India PRwire (
India PRwire disclaims any content contained in press release. Use of our service is governed by our privacy policy and terms of service.


Alternative white paper.indd

Safer Britain, Safer WorldThe decision not to replace Trident The decision on whether or not to replace Britain’s nuclear weapons system must be taken on the basis of what will most contribute to the security of the British people. A decision not to replace Trident will best meet that requirement. It will strengthen the international disarmament and non-proliferation regime

Procedure medicatie

PROCEDURE MEDICATIE OP INTERNAAT Het internaat neemt de nodige maatregelen om eerste hulp te kunnen bieden. De beide internaten beschikken over een gepast verzorgingslokaal, waar een gewonde of zieke leerling in comfortabele omstandigheden en in een geschikte houding (doorgaans liggend) kan rusten. Het internaat telt meerdere personeelsleden die over een getuigschrift van hulpverlener besc

Copyright 2014 Pdf Medic Finder